Exhibit 99.1
JOINT FILING AGREEMENT
In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the shares of Common Stock, $.01 par value per share, of CASI Pharmaceuticals, Inc., a Delaware corporation. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.
Dated: June 21, 2022
ETP GLOBAL FUND L.P. | |||
By: | EMERGING TECHNOLOGY PARTNERS, LLC General Partner | ||
By: | /s/ Wei-Wu He, Ph.D. | ||
Name: | Wei-Wu He, Ph.D. | ||
Title: | Managing Member |
EMERGING TECHNOLOGY PARTNERS, LLC | |||
By: | /s/ Wei-Wu He, Ph.D. | ||
Name: | Wei-Wu He, Ph.D. | ||
Title: | Managing Member |
ETP-BIOHEALTH FUND III L.P. | |||
By: EMERGING TECHNOLOGY PARTNERS, LLC General Partner | |||
By: | /s/ Wei-Wu He, Ph.D. | ||
Name: | Wei-Wu He, Ph.D. | ||
Title: | Managing Member |
HUIYING MEMORIAL FOUNDATION | |||
By: | /s/ Wei-Wu He, Ph.D. | ||
Name: | Wei-Wu He, Ph.D. | ||
Title: | President | ||
/s/ Wei-Wu He, Ph.D. | |
Wei-Wu He, Ph.D. |